Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine
2020 · Neoplasia · 61 citations
https://doi.org/10.1016/j.neo.2020.11.005
J
Jens Hoffmann
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
378
Papers
4.2K
Citations
35
h-index
71
i10-index
Jens Hoffmann is an academic researcher from Fraunhofer Institute for Solar Energy Systems. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Cancer Research and Treatments & Cancer Genomics and Diagnostics. The author has an h-index of 35, co-authored 322 publications.
ORCID: 0000-0003-3880-1658Papers by this author
worksBasal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer
2017 · International Journal of Cancer · 37 citations
https://doi.org/10.1002/ijc.30808
Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker
2022 · British Journal of Cancer · 27 citations
https://doi.org/10.1038/s41416-022-01833-3
Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
1999 · PubMed · 19 citations
Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain
2017 · Scientific Reports · 10 citations
https://doi.org/10.1038/s41598-017-09460-2
Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts
2022 · Communications Biology · 7 citations
https://doi.org/10.1038/s42003-022-03016-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat